|
Patent landscape, scope, and claims: |
United States Patent 10,874,671 (Nilotinib) Amorphous Solid Dispersion: Claim Scope, Coverage Boundaries, and Patent Landscape
US Drug Patent 10,874,671 claims amorphous solid dispersions of nilotinib as either nilotinib fumarate or nilotinib tartrate, with control over dispersion composition (carrier and optional organic acids), manufacturing route (hot-melt extrusion or spray drying), performance attributes (fasted vs fed bioavailability targets), and multiple composition/product features (granule-based tablets, stability, impurity limits, and “no regard to food” instructions). The estate is broad at the “solid dispersion” level but narrows via specific feature requirements: amorphous form thresholds, XRD profile matching, carrier selections, optional organic acid list, specific ratio bands, and downstream formulation constructs.
What exactly is claimed in US Patent 10,874,671 for nilotinib amorphous solid dispersions?
Independent claim anchor
- Claim 1: An amorphous solid dispersion comprising nilotinib fumarate or nilotinib tartrate.
Core dependent claim stack
- Claim 2: Claim 1 dispersion + pharmaceutically acceptable carrier, optionally ≥1 organic acid.
- Claim 3: Claim 2 dispersion prepared by hot-melt extrusion or spray-drying.
- Claims 4-8: Define quantitative and compositional boundaries:
- Claim 4: weight ratio of (nilotinib salt):(carrier) ~1:1 to ~1:6, preferred ~1:3 to ~1:4.
- Claim 5: carrier is selected from a defined list including:
- HPMC-AS, PVP/VA, HPMCP, HPMC, PEG, HPC, CMC, PVP, and mixtures.
- Claim 6: optional organic acid is selected from a defined list including:
- acetic, propionic, octanoic/decanoic/dodecanoic, glycolic, lactic, fumaric, succinic, adipic, pimelic, malic, tartaric, citric, glutamic, aspartic, maleic, benzoic, salicylic, phthalic, phenylacetic, cinnamic, ascorbic; and mixtures.
- Claim 7: optional organic acid ratio band:
- (nilotinib salt):(organic acid) ~1:0.5 to ~1:5, preferred ~1:2, more preferred ~1:1.
- Claim 8: additional excipients allowed (diluents, binders, disintegrants, lubricants, glidants, surfactants, solubilizers, plasticizers, stabilizers, antioxidants, combinations).
Downstream product claims
- Claim 9: Pharmaceutical composition containing an amorphous solid dispersion that provides enhanced bioavailability vs a reference formulation in fasted state.
- Claims 10-13: dose range, dosage forms, excipient options, and manufacturing methods:
- Claim 10: 25 mg to 200 mg nilotinib salt.
- Claim 11: tablet/capsule/caplet/beads/granules/oral suspension.
- Claim 12: excipients list.
- Claim 13: composition obtained by direct compression, wet granulation, or dry granulation.
- Claim 14: tablet architecture:
- (a) dispersion as granules
- (b) intra-granular excipient
- (c) extra-granular excipient
- (d) optional coating
- Claim 15: stability target for composition:
- ≥6 months at 40°C/75% RH or 25°C/60% RH.
- Claim 16: impurity limit:
- unknown impurity <0.2% w/w, preferably <0.15%, more preferably <0.1% (HPLC).
- Claim 17: kit with instructions indicating administration “without regard to food.”
- Claim 18: fasted vs fed PK window:
- at least one PK parameter (AUC0-infinity, Cmax, AUC0-t, or combinations) in fasted state is ~80% to ~125% of the corresponding fed-state parameter.
- Claims 19-21: amorphous fraction thresholds:
- substantially amorphous
- ≥80% amorphous
- ≥90% amorphous
- Claims 22-23: XRD characterization requirements:
- dispersion has XRD profile “substantially as shown in FIG. 2” and/or “substantially as shown in FIG. 3.”
What is the practical claim boundary?
A design-around is most feasible by changing at least one required limiting feature:
- switch away from nilotinib fumarate/tartrate to a different salt form (if not covered by other claims),
- replace excluded carriers (outside the specific list) or change dispersion composition ratios out of the claim band,
- change manufacturing route away from hot-melt extrusion and spray-drying (if those methods are used as limiting features in claim construction),
- avoid the claimed amorphous content thresholds and/or XRD profile match,
- avoid the claimed fasted PK relationship and enhanced fasted bioavailability requirement,
- omit the claimed tablet/granule architecture (claim 14) or the “no regard to food” kit instruction (claim 17).
How broad are the composition claims vs the formulation and performance claims in US 10,874,671?
High-level breadth (composition)
- Claim 1 is structurally simple: amorphous solid dispersion of nilotinib fumarate/tartrate.
- Claim 2 adds a carrier (broad concept) and optional organic acids (still bounded by a list in claim 6).
Moderate narrowing (method and composition specifics)
- Claim 3 limits to dispersions made by hot-melt extrusion or spray drying.
- Claims 4-7 impose defined ratio ranges and carrier/acid identity.
Narrower and litigable (performance and characterization)
- Claims 9, 18, and 17 are tied to fasted outcomes:
- claim 9: “enhanced bioavailability vs reference formulation in fasted state”
- claim 18: fasted PK parameter within 80%–125% of fed-state
- claim 17: explicit “without regard to food” instruction (kit)
- Claims 19-23 are constrained by amorphous fraction and XRD profiles. These are often strong evidentiary hooks in infringement and validity disputes because they can be tested with standard analytical methods.
Featured-snippet answer
US 10,874,671 is broad at the concept level (amorphous solid dispersions of nilotinib fumarate or tartrate), then narrows through specific carriers, optional organic acids, ratio bands, preparation methods, amorphous fraction, XRD profile matching, and fasted performance metrics.
What formulations are protected: tablets, granules, beads, oral suspension, and “granule-in-tablet” architectures?
Dosage forms explicitly claimed (Claim 11)
- tablets, capsules, caplets
- beads, granules
- oral suspension
Formulation construction (Claim 14)
- tablet with:
- dispersion in granular form
- intra-granular excipients
- extra-granular excipients
- optional coating
Manufacturing routes (Claim 13)
- direct compression
- wet granulation
- dry granulation
Stability and impurity requirements (Claims 15-16)
- stability at specified accelerated/long-term conditions
- impurity threshold (unknown impurity) by HPLC
Kit packaging and labeling (Claim 17)
- kit includes composition plus instructions for oral administration indicating no food effect.
When does the patent expire and what exclusivity drivers matter for launch timing?
No expiration timing data is included in the prompt for US 10,874,671 (no filing date, priority date, or patent term adjustment/effective filing data). Without those inputs, expiration/exclusivity timelines cannot be stated without risk of error.
What generic entry risks exist for nilotinib fumarate/tartrate amorphous solid dispersions?
Risk concentration points
- If a generic targets a nilotinib salt and creates an amorphous solid dispersion using the same carriers (HPMC-AS, PVP/VA, HPMCP, HPMC, PEG, HPC, CMC, PVP), and optionally includes one of the listed organic acids at the claimed ratio bands, the probability of hitting Claims 1-8 rises sharply.
- If the generic also pursues comparable fasted performance (Claim 9 enhanced fasted bioavailability vs reference; Claim 18 fasted PK within 80%–125% of fed-state), risk expands into performance claims.
- If the generic’s dispersion is confirmed to have:
- ≥80% or ≥90% amorphous content (Claims 20-21), and/or
- XRD profiles substantially similar to FIG. 2 and/or FIG. 3 (Claims 22-23),
the evidentiary overlap tightens.
Higher leverage design-arounds
- Use different nilotinib salt (not fumarate/tartrate), if feasible in the regulatory strategy.
- Use carriers outside the named list, or adjust salt:carrier and salt:acid ratios out of the recited bands.
- Avoid hot-melt extrusion and spray drying routes.
- Target a formulation that does not satisfy the fasted PK constraint (Claim 18) and does not meet “enhanced bioavailability in fasted state” claim framing (Claim 9), supported by comparative pharmacokinetic studies against the claimed “reference formulation.”
What does the patent say about fasted vs fed bioavailability and pharmacokinetic targets?
Claim 9 (bioavailability comparison)
- Pharmaceutical composition provides enhanced bioavailability in the fasted state compared to a reference formulation.
Claim 18 (numerical PK relationship)
- One or more PK parameters (AUC0-infinity, Cmax, AUC0-t, or combinations) in fasted state fall in 80% to 125% range of fed-state.
Claim 17 (labeling/instruction construct)
- Kit instructions indicate administration in humans without regard to food.
Litigation relevance
Fast/fed claims typically drive infringement arguments through:
- comparative PK study design
- analytical verification of salt form, amorphous content, and dispersion structure
- formulation reproducibility and stability data
How many patents cover these dispersion features, and which companies own the landscape?
The prompt provides only the claims text for US 10,874,671 and does not include:
- the patent’s bibliographic data (assignee, inventors, publication numbers)
- related continuation/divisional family members
- citing/cited patents or portfolio mappings
- Orange Book listings or FDA reference product identifiers
Without those, an “estate-wide” coverage count across related US patents cannot be generated reliably.
What other US patent claims would likely be adjacent in a nilotinib amorphous dispersion portfolio?
Based on the claim structure, the neighborhood risk usually includes:
- additional amorphous dispersion compositions with different carriers and salts
- additional dispersion characterization sets (alternate XRD figures/patterns)
- alternate manufacturing parameters for hot-melt extrusion or spray drying
- tablet-in-tablet or granulation method variations
- excipient compositions and coatings
- alternative performance claims for fasted PK or food-effect reduction
- impurity profile and stability-driven claims
No specific patent numbers are provided in the prompt, so this is a technical expectation of claim clustering rather than an identified list of enforceable rights.
Key Takeaways
- US 10,874,671 centers on amorphous solid dispersions of nilotinib fumarate or nilotinib tartrate.
- The patent’s enforceable scope is constrained by specific carriers (claim 5), optional organic acids (claims 6-7), salt-to-carrier and salt-to-acid ratios (claims 4 and 7), and manufacturing route (claim 3).
- Formulation/product claims cover multiple oral dosage forms and include a tablet granule architecture (claim 14), stability (claim 15), and unknown impurity limits (claim 16).
- The highest-fidelity hooks are the fasted vs fed performance requirements (claims 9 and 18) plus amorphous fraction and XRD profile matching (claims 19-23).
- A credible generic design-around must address at least one of the limiting features: salt identity, carrier identity, ratio bands, manufacturing method, amorphous fraction/XRD match, and fasted PK/bioavailability targets.
FAQs
-
Does US 10,874,671 cover crystalline nilotinib salts embedded in a matrix?
The claims are directed to amorphous solid dispersions with amorphous fraction and/or XRD characterization requirements in dependent claims.
-
Can a generic avoid infringement by choosing a different carrier than HPMC-AS, HPMC, or PVP/VA?
Claims 5-8 define specific carrier lists for covered embodiments; moving outside those selections is a primary potential boundary.
-
If a formulation shows improved fasted exposure, does it automatically fall under claim 18?
Claim 18 requires a specific numeric fasted vs fed PK relationship (80%–125% for selected parameters).
-
Are XRD profile requirements only evidentiary, or do they limit claim scope?
Dependent claims 22-23 add characterization limitations tied to “substantially as shown” in specific figures.
-
Is a “without regard to food” instruction required for all infringement scenarios?
Claim 17 is a kit/instructions claim; it is not the foundation of claim 1 but may apply to label/kit constructs.
References
- US Patent 10,874,671 (claim text provided in prompt).
More… ↓
⤷ Start Trial
|
